TriSalus Life Sciences Inc.
NASDAQ: TLSI · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-04
TriSalus Life Sciences Inc. (TLSI) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2021 | $8.40M | $-28.84M | 85.80% | -286.06% | -343.35% |
| 2022 | $12.40M | $-47.19M | 81.79% | -293.91% | -380.60% |
| 2023 | $18.51M | $-59.36M | 85.93% | -294.28% | -320.69% |
| 2024 | $29.43M | $-33.23M | 86.06% | -122.88% | -112.92% |
| 2025 | $45.15M | $-39.23M | 84.57% | -59.68% | -86.88% |
Frequently asked questions
What is TriSalus Life Sciences Inc.'s revenue?
TriSalus Life Sciences Inc.'s trailing twelve-month revenue is $44.88M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is TLSI?
In its most recent fiscal year, TLSI ran a gross margin of 84.57%, an operating margin of -59.68%, and a net margin of -86.88%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does TLSI generate?
TLSI produced $-18.93M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is TLSI's balance sheet healthy?
TLSI holds $20.44M in cash and equivalents against $33.05M in long-term debt, on $-33.86M of shareholder equity. That debt is best read against the cash flow the business throws off each year.